Tag: DGCI
Govt clarifies on MDR-TB drug ‘Bedaquiline’ controversy
The union health ministry has clarified that the Bedaquiline which is used in selective cases, is available only through Revised National TB Control Programme (RNTCP) and open market sale of the drug is not permitted in India as of now...…………..
DCGI’s green signal to Mylan’s launch of Avonza in India
The new drug by Mylan offers an innovative, reduced-dose alternative first-line regimen for people being treated for HIV/AIDS in India.........